WALD - Waldencast plc
Data from the ALOHA Program and NU-GEN™ Cellular Renewal Serum Showcase Results to Help Drive Practice Success Data from the ALOHA Program and NU-GEN™ Cellular Renewal Serum Showcase Results to Help Drive Practice Success
A multi-city pop-up introducing consumers to the future of skincare and longevity innovation A multi-city pop-up introducing consumers to the future of skincare and longevity innovation
Sun Shield™ Mineral UV Barrier Protect Broad Spectrum SPF 40 delivers advanced mineral protection with skincare benefits for daily defense Sun Shield™ Mineral UV Barrier Protect Broad Spectrum SPF 40 delivers advanced mineral protection with skincare benefits for daily defense
LONDON, April 28, 2026 (GLOBE NEWSWIRE) -- Waldencast plc (NASDAQ: WALD) (“Waldencast” or the “Company”), a global multi-brand beauty and wellness platform, announced today that it was notified by the staff of the U.S. Securities and Exchange Commission (the “SEC”) that they have concluded their investigation of the Company relating to Waldencast's restatement of its financial results and material weaknesses in its internal control over financial reporting related to historical accounting practices used by Obagi Cosmeceuticals (the “Investigation”) and, based on the information available as of the date of the notice, the SEC does not intend to recommend an enforcement action against Waldencast.
Waldencast PLC (NASDAQ: WALD - Get Free Report) saw a significant increase in short interest during the month of March. As of March 13th, there was short interest totaling 1,205,249 shares, an increase of 61.6% from the February 26th total of 745,941 shares. Currently, 0.9% of the shares of the company are sold short. Based on
The clinically proven formula pairs NAD+ with its precursors to replenish skin cells and address nine signs of skin aging for healthier, more resilient-looking skin The clinically proven formula pairs NAD+ with its precursors to replenish skin cells and address nine signs of skin aging for healthier, more resilient-looking skin
ProMD's multi-location physician led network will participate in Obagi's ALOHA Program as part of a structured evaluation of MagIQ and integrated skincare protocols to providers across multiple states ProMD's multi-location physician led network will participate in Obagi's ALOHA Program as part of a structured evaluation of MagIQ and integrated skincare protocols to providers across multiple states
Shares of Waldencast PLC (NASDAQ: WALD - Get Free Report) have received an average rating of "Moderate Buy" from the six research firms that are covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to
FY 2025 net revenue of $272.1 million, flat to FY 2024, and Adjusted EBITDA of $16.1 million Q4 2025 net revenue of $72.0 million, flat to Q4 2024 and Adjusted EBITDA of $6.6 million Obagi Medical sees continued revenue acceleration as a result of transformation efforts and continued brand momentum, alongside investments supporting the recent launch of its injectables platform Milk Makeup maintains U.S. consumption growth through distribution expansion, offset by softness in international markets Waldencast advanced its strategic priorities in 2025, entering medical aesthetics, and strengthening its financial flexibility through the sale of the Obagi Japan trademark and the refinancing of its credit facility. As a result, the Company enters 2026 with a strong foundation for successful growth LONDON, March 13, 2026 (GLOBE NEWSWIRE) -- Waldencast plc (NASDAQ: WALD) (“Waldencast” or the “Company”), a global multi-brand beauty and wellness platform, today reported operating results for the three months ended December 31, 2025 (“Q4 2025”) and year ended December 31, 2025 (“Year Ended 2025”) on Form 6-K to the U.S. Securities and Exchange Commission (the “SEC”), which are also available on our investor relations site at http://ir.waldencast.com/.
LONDON, March 11, 2026 (GLOBE NEWSWIRE) -- Waldencast plc, (NASDAQ: WALD) (“Waldencast”), a global multi-brand beauty and wellness platform announced that its Fourth Quarter and Fiscal Year 2025 earnings will be issued in a press release on March 13, 2026, prior to U.S. market open. The Company does not plan to host a conference call to discuss results given its ongoing strategic review.
Schweiger selected as a leading dermatology platform partner due to its commitment to clinical excellence, rapid access to care, and dissemination across its extensive national network of practices Schweiger selected as a leading dermatology platform partner due to its commitment to clinical excellence, rapid access to care, and dissemination across its extensive national network of practices
It's a Secret Med Spa selected as a premier luxury med spa partner due to its commitment to excellence, personalized luxury aesthetic experiences, and outstanding patient results across its growing network of high-end locations It's a Secret Med Spa selected as a premier luxury med spa partner due to its commitment to excellence, personalized luxury aesthetic experiences, and outstanding patient results across its growing network of high-end locations
Aesthetic Record selected as a leading aesthetics EMR and practice management partner due to its commitment to technology innovation, operational efficiency, and supporting thousands of aesthetic practices nationwide Aesthetic Record selected as a leading aesthetics EMR and practice management partner due to its commitment to technology innovation, operational efficiency, and supporting thousands of aesthetic practices nationwide
Shares of Waldencast PLC (NASDAQ: WALD - Get Free Report) have received an average recommendation of "Moderate Buy" from the six ratings firms that are currently covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and four have given a buy recommendation to
DermFx selected as a leading regional med spa partner due to its commitment to exceptional patient care, aesthetic innovation, and excellence across Southern California practices DermFx selected as a leading regional med spa partner due to its commitment to exceptional patient care, aesthetic innovation, and excellence across Southern California practices
Moxie selected as a leading aesthetic practice software and support partner for its commitment to innovation, compliance, and empowering aesthetic entrepreneurs Moxie selected as a leading aesthetic practice software and support partner for its commitment to innovation, compliance, and empowering aesthetic entrepreneurs
The dermatologist-tested duo pairs gentle chemical resurfacing with daily hydration and SPF protection for visibly smoother lips The dermatologist-tested duo pairs gentle chemical resurfacing with daily hydration and SPF protection for visibly smoother lips
VIO Med Spa selected as a key med spa franchise partner for its commitment to clinical excellence, innovation, and nationwide scalable aesthetic care VIO Med Spa selected as a key med spa franchise partner for its commitment to clinical excellence, innovation, and nationwide scalable aesthetic care
Next Health selected as a leading wellness and longevity partner given its innovative approach to personalized aesthetics and health optimization Next Health selected as a leading wellness and longevity partner given its innovative approach to personalized aesthetics and health optimization
Alpha selected as the first Medspa platform partner given their commitment to innovation, education, and breaking through barriers Alpha selected as the first Medspa platform partner given their commitment to innovation, education, and breaking through barriers